{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T10:31:44Z","timestamp":1752229904278,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Infusion-related reactions (IRRs) are major side effects of rituximab administration. Male sex, high body weight, body surface area (BSA), and body mass index are predictive markers of rituximab-induced IRRs. However, as rituximab was not administered at a fixed dosage in a previous study, whether a higher dosage or factors associated with a larger physique are more strongly associated with rituximab-induced IRRs is unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Main body<\/jats:title>\n                <jats:p>Thirteen adults with frequently relapsing minimal change nephrotic syndrome (MCNS) who received an initial rituximab dose of 500\u00a0mg between September 2015 and November 2022 were retrospectively evaluated. Data on IRRs were collected from medical records. The incidence of rituximab-induced IRRs was 38.5% (5\/13). The IRR group had a significantly higher BSA than the non-IRR group (median, 1.86 vs. 1.48 m<jats:sup>2<\/jats:sup>; <jats:italic>p<\/jats:italic>\u2009=\u20090.045). Additionally, rituximab dosage normalized by BSA in the IRR group was significantly lower than that in the non-IRR group (median, 268.8 vs. 337.9 mg\/m<jats:sup>2<\/jats:sup>; <jats:italic>p<\/jats:italic>\u2009=\u20090.045).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study revealed that adults with frequently relapsing MCNS who experienced IRRs tend to have a higher BSA, even with fixed-dose rituximab treatment. Therefore, when patients with higher BSA receive rituximab treatment, clinicians should be careful about monitoring patient condition whether the dosage is fixed or not.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40780-024-00334-0","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T08:04:43Z","timestamp":1708589083000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patients with infusion-related reactions on fixed-dose rituximab treatment have higher body surface area than those without infusion-related reactions in adults with frequently relapsing minimal change nephrotic syndrome: a retrospective study"],"prefix":"10.1186","volume":"10","author":[{"given":"Hironobu","family":"Nishiura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2649-4638","authenticated-orcid":false,"given":"Masaya","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhito","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Emoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutaka","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"334_CR1","doi-asserted-by":"publisher","first-page":"iv100","DOI":"10.1093\/annonc\/mdx216","volume":"28","author":"S Rosell\u00f3","year":"2017","unstructured":"Rosell\u00f3 S, Blasco I, Gar\u0107a Fabregat L, Cervantes A, Jordan K. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice guidelines. Annals of Oncology. 2017;28:iv100\u201318.","journal-title":"Annals of Oncology"},{"key":"334_CR2","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1634\/theoncologist.2008-0012","volume":"13","author":"CH Chung","year":"2008","unstructured":"Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008;13:725\u201332.","journal-title":"Oncologist"},{"key":"334_CR3","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/BF02780531","volume":"17","author":"H Hagberg","year":"2000","unstructured":"Hagberg H, Holmbom E. Risk factors for side effects during first infusion of rituximab-definition of a low risk group. Med Oncol. 2000;17:218\u201321.","journal-title":"Med Oncol"},{"key":"334_CR4","first-page":"2022","volume":"3688727","author":"S Ohata","year":"2022","unstructured":"Ohata S, Takenaka K, Sugiyama D, Sugimoto T. Bone marrow infiltration is a distinctive risk factor for Rituximab infusion-related reactions in CD20-Positive B-Cell Non-hodgkin Lymphoma. Adv Hematol. 2022;3688727:2022.","journal-title":"Adv Hematol"},{"key":"334_CR5","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.clml.2019.08.001","volume":"19","author":"KE Kowalski","year":"2019","unstructured":"Kowalski KE, Adams CB, Voils SA, Wheeler SE. Use of patient and disease characteristics as predictive indicators of Rituximab infusion-related reactions in adult malignant hematology patients at an Academic Medical Center. Clin Lymphoma Myeloma Leuk. 2019;19:723\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"334_CR6","first-page":"674","volume":"70","author":"T Tachi","year":"2015","unstructured":"Tachi T, Yasuda M, Usui K, Umeda M, Nagaya K, Osawa T, et al. Risk factors for developing infusion reaction after rituximab administration in patients with B-cell non-hodgkin\u2019s lymphoma. Pharmazie. 2015;70:674\u20137.","journal-title":"Pharmazie"},{"key":"334_CR7","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1248\/bpb.b23-00157","volume":"46","author":"H Nishiura","year":"2023","unstructured":"Nishiura H, Takahashi M, Iwai T, Uchida J, Nakamura Y. Analysis of risk factors for infusion-related reactions following Rituximab Administration in patients with desensitization before renal transplantation. Biol Pharm Bull. 2023;46:1332\u20137.","journal-title":"Biol Pharm Bull"},{"key":"334_CR8","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. KDIGO 2021 Clinical Practice Guideline for the management of glomerular diseases. Kidney Int. 2021;100:S1\u2013276.","journal-title":"Kidney Int"},{"key":"334_CR9","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako DM, Nozu K, Mori R, Tuchida N, Kamei K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. 2014;384:1273\u201381.","journal-title":"The Lancet"},{"key":"334_CR10","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1093\/ndt\/gfs515","volume":"28","author":"T Takei","year":"2013","unstructured":"Takei T, Itabashi M, Moriyama T, Kojima C, Shiohira S, Shimizu A, et al. Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults. Nephrol Dial Transplant. 2013;28:1225\u201332.","journal-title":"Nephrol Dial Transplant"},{"key":"334_CR11","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"334_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10157-015-1139-6","volume":"20","author":"Y Miyabe","year":"2016","unstructured":"Miyabe Y, Takei T, Iwabuchi Y, Moriyama T, Nitta K. Amelioration of the adverse effects of prednisolone by rituximab treatment in adults with steroid-dependent minimal-change nephrotic syndrome. Clin Exp Nephrol. 2016;20:103\u201310.","journal-title":"Clin Exp Nephrol"},{"key":"334_CR13","first-page":"853","volume":"18","author":"P Donald","year":"1958","unstructured":"Donald P. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res. 1958;18:853\u20136.","journal-title":"Cancer Res"},{"key":"334_CR14","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.msard.2018.11.027","volume":"27","author":"WL Conte","year":"2019","unstructured":"Conte WL, Arndt N, Cipriani VP, Dellaria A, Javed A. Reduction in ocrelizumab-induced infusion reactions by a modified premedication protocol. Mult Scler Relat Disord. 2019;27:397\u20139.","journal-title":"Mult Scler Relat Disord"},{"key":"334_CR15","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1146\/annurev-immunol-031210-101322","volume":"29","author":"MF Gregor","year":"2011","unstructured":"Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011;29:415\u201345.","journal-title":"Annu Rev Immunol"},{"key":"334_CR16","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1159\/000443073","volume":"38","author":"X Zhai","year":"2016","unstructured":"Zhai X, Qian G, Wang Y, Chen X, Lu J, Zhang Y, et al. Elevated B cell activation is Associated with type 2 Diabetes Development in obese subjects. Cell Physiol Biochem. 2016;38:1257\u201366.","journal-title":"Cell Physiol Biochem"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-024-00334-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-024-00334-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-024-00334-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T08:17:39Z","timestamp":1708589859000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-024-00334-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["334"],"URL":"https:\/\/doi.org\/10.1186\/s40780-024-00334-0","relation":{},"ISSN":["2055-0294"],"issn-type":[{"type":"electronic","value":"2055-0294"}],"subject":[],"published":{"date-parts":[[2024,2,22]]},"assertion":[{"value":"15 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study adhered to the guidelines of the 1964 Declaration of Helsinki and its later amendments and was approved by the institutional review board of the Osaka Metropolitan University Hospital, which waived the requirement for informed consent owing to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KM received research funding from Mitsubishi Tanabe Pharma Corporation, Sanofi K.K., Kyowa Kirin, and Sumitomo Pharma and received a Speaker\u2019s Bureau from Mitsubishi Tanabe Pharma Corporation, AstraZeneca K.K., Nippon Boehringer Ingelheim, Mochida Pharmaceutical, and Kyowa Kirin. ME received research funding from Mitsubishi Tanabe Pharma Corporation, Kyowa Kirin, Sumitomo Pharma, Eisai, Chugai Pharmaceutical, Bayer Yakuhin, and Nippon Boehringer Ingelheim, and received a Speaker\u2019s Bureau from AstraZeneca K.K., Nippon Boehringer Ingelheim, Sumitomo Pharma, Sanofi, Ono Pharmaceutical and Kyowa Kirin.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}